We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A New Drug Inhibits the Alternative Splicing of Self-Renewal and Survival Genes that Protects Leukemia Stem Cells from Chemotherapy

By LabMedica International staff writers
Posted on 06 Feb 2013
Drug resistant leukemia stem cells (LSCs) that are sequestered in the bone marrow can be sensitized to the action of tyrosine kinase inhibitors (TKIs) such as imatinib, gifitinib, and sunitinib by treatment with the investigatory drug sabutoclax.

Investigators at the University of California, San Diego School of Medicine (USA) and other institutions including the Sanford-Burnham Medical Research Institute (La Jolla, CA, USA) have found that alternative splicing of BCL-2 genes in LSCs favored the expression of prosurvival proteins that protected the insipient cancer cells from drug treatments.

Alternative splicing is a process by which the exons of the RNA produced by transcription of a gene are reconnected in multiple ways during RNA splicing. More...
The resulting different mRNAs may be translated into different protein isoforms, thereby allowing a single gene to code for multiple proteins. Alternative splicing occurs as a normal phenomenon in eukaryotes, where it greatly increases the biodiversity of proteins that can be encoded by the genome. In humans, about 95% of multiexonic genes are alternatively spliced. Numerous modes of alternative splicing have been observed, of which the most common is exon skipping. In this mode, a particular exon may be included in mRNAs under some conditions or in particular tissues, and omitted from the mRNA in others. Abnormal variations in splicing have also been implicated in disease, since a large proportion of human genetic disorders result from splicing variants. Abnormal splicing variants are also thought to contribute to the development of cancer.

Results appearing in the January 17, 2013, online issue of the journal Cell Stem Cell revealed that sabutoclax, a pan-BCL-2 inhibitor rendered LSCs sequestered in the bone marrow sensitive to TKIs at doses that spared normal progenitors. Furthermore, sabutoclax destroyed cells by suppressing some members of the Bcl-2 protein family. Bcl-2 proteins are involved in apoptosis, the normal cellular process of programmed cell death. Sabutoclax blocked anti-apoptotic Bcl-2 proteins that would otherwise have kept the cancer cells from dying.

“Our findings show that pan-BCL-2 inhibition will be critical for the eradication of cancer stem cells in chronic myeloid leukemia and that there is an essential link between cancer stem cell dormancy, pro-survival BCL-2 isoform expression, and therapeutic resistance,” said senior author Dr. Catriona H. M. Jamieson, associate professor of medicine at the University of California, San Diego. “By using a novel pan-BCL-2 inhibitor, we may be able to prevent therapeutic resistance by sensitizing malignant stem cell clones to TKIs.”

Related Links:
University of California, San Diego School of Medicine
Sanford-Burnham Medical Research Institute


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.